AVIX Pharmaceuticals Limited

We are solving the problem by making AMR (antimicrobial resistance) infections treatable again. There are no questions about the need for new novel class of antibiotics to combat current and future antibiotic resistance to save humanity from socioeconomic disaster. Until these novel class antibiotics discovered, we are developing repurposed drug discovery pipeline which are 70x cheap, 4x time-efficient and patentable to develop new antibiotics, a potentially revolutionary solution to treat antibiotic resistant bacteria. We are planning to re-sensitize bacteria to available antibiotics by repurposing approved drugs to shorten drug development time & cost. We are initially focusing on developing oral ARB (antibiotic resistance breaker) cocktails for treating urinary tract infections (UTIs). ARB cocktails will use synergistic action of various combinations of FDA approved antibiotic and non-antibiotic drugs and Nutraceuticals (supplement/food ingredients) as ARB. Overall, a drug repurposing strategy provides an attractive business opportunity with a high return on capital. Our resistance-breaking repurposed antibiotic cocktail will effectively treat drug resistant bacteria in the community and will reduce the number of hospital admissions as well as facilitate early discharge from the hospital. During this antibiotic development, AVIX is looking to establish a pipeline of repurposed pre-clinical drug discovery to combat multidrug resistant bacteria. This pipeline will provide attractive business opportunities to develop pathogen-specific antibiotic cocktails.